SGLT2 inhibitors – moving on with the evidence (2019)

Type of publication:
Journal article

*Morris, David

Journal of Diabetes Nursing; Jun 2019; vol. 23 (no. 4); p. 1-9

The evidence base on the benefits and risks of using sodium-glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycaemia has grown in recent years, with data showing potential cardiovascular and renal benefits, along with safety concerns that warrant cautious use and monitoring in certain users. This article reviews the benefits and difficulties associated with the use of SGLT2 inhibitors in people with type 2 diabetes and, potentially, type 1 diabetes.